TME Hypoxia & Acidity Assessment Service

Hypoxia and Acidity Impair CD8⁺ T Cell Function

The oxygen-starved, acidic nature of tumor microenvironments (TME) directly cripples CD8⁺ T cell functionality, sabotaging anti-tumor immune defenses. Low oxygen levels compromise these immune cells through three coordinated strikes: ramping up inhibitory receptors that blunt activation signals, starving their energy reserves by disrupting oxidative phosphorylation-mediated ATP production, and intensifying competition for glucose and amino acids. Meanwhile, the acidic pH pervasive in solid tumors throws a wrench into critical signaling networks—particularly IL-2 survival signals and mTORC1-driven metabolic adaptation—leaving CD8⁺ T cells unable to multiply efficiently, secrete tumor-killing cytokines like IFN-γ, or deploy cytotoxic granules. These dual microenvironmental challenges collectively establish an immunological "blind spot," where disabled T cells fail to police malignant growth, granting tumors free rein to advance undetected.

Fig.1 Extracellular vesicles secreted by acidic or hypoxic tumor cells and their effects on recipient cells.¹

TME Hypoxia and Acidity Assessment Service at Creative Biolabs

Creative Biolabs provides a comprehensive TME hypoxia and acidity assessment service for global customers with a detailed and accurate characterization of the tumor microenvironment. Our platform employs cutting-edge methodologies, including hypoxia marker immunohistochemistry, hypoxia-specific probes, and dual-modal pH quantification via microelectrode arrays paired with radiometric fluorescent dyes. These techniques synergize to map spatial-temporal variations in oxygen tension and proton gradients across tumor niches.

The service portfolio extends to metabolic profiling through lactate flux quantification and pathway-specific enzyme activity assays, complemented by advanced imaging workflows that resolve 3D hypoxia/acidosis distributions at sub-millimeter resolution. By correlating TME parameters with tumor proliferation kinetics, treatment resistance biomarkers, and metastatic potential, we equip research and clinical teams with actionable insights for therapeutic development and patient stratification. This multidimensional profiling supports data-driven strategies to counteract microenvironment-mediated immunosuppression and improve oncology outcomes.

Advantages

• Customer-specific design
• Modern and diverse methodologies
• High accuracy and reliability
• In-depth metabolic analysis
• Advanced imaging capabilities
• Expert analysis and interpretation

Associated Services

In addition to TME hypoxia and acidity assessment services, we also provide a range of characterization services to evaluate the metabolic characteristics of tumor cells and immune cells under physiological conditions or in the tumor microenvironment, such as glucose uptake, amino acid utilization, and so on, which include:

• Physiological CD8⁺ T Cell Metabolic Profiling Service
• Tumor Microenvironment (TME) CD8⁺ T Cell Metabolic Profiling Service
• Glucose Uptake Quantification Service
• Amino Acid Utilization Analysis Service
• Comprehensive Metabolite Profiling Service
• Key Cytokine Expression Analysis Service

Work with Creative Biolabs

Creative Biolabs' TME hypoxia and acidity evaluation service provides global customers with critical information for gaining a thorough understanding of the tumor microenvironment through its comprehensiveness, accuracy, and cutting-edge technology. We are able to accurately characterize the TME that influences tumor behavior, treatment response, and prognosis through a variety of modern technologies. Our expert analysis and interpretation are intended to assist researchers and clinicians in making more informed judgments about cancer research and clinical applications, ultimately fostering innovation and advancement in tumor therapy. If you're interested in our service, please get in touch with us at your convenience.

Reference

1. Peppicelli, Silvia, et al. "Acidity and hypoxia of tumor microenvironment, a positive interplay in extracellular vesicle release by tumor cells." Cellular Oncology (2024): 1-15. Distributed under Open Access License CC BY 4.0, without modification.